Goldman Sachs Views Lab Stocks as Attractive, Neutral on Diagnostics; LabCorp (LH) Top Pick, Myriad (MYGN) the Bottom
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Qiagen (QGEN) Agrees to Acquire STAT-Dx
January 31, 2018 4:35 PM ESTQIAGEN N.V. (NYSE: QGEN) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
The... More
Qiagen (QGEN) Tops Q4 EPS by 2c, Beats on Revenues; 'Sets FY18 Outlook for Further Growth in Adj. Net Sales & Adj. EPS'
January 31, 2018 4:15 PM ESTQiagen (NASDAQ: QGEN) reported Q4 EPS of $0.43, $0.02 better than the analyst estimate of $0.41. Revenue for the quarter came in at $396.6 million versus the consensus estimate of $393.33 million.
Solid Q4 results as QIAGEN achieves full-year 2017 targets: Q4 2017: Net sales $396.9 million (+8% actual, +5% CER);... More